Shimmer Research today announced the launch of a healthcare industry open source initiative for wearable sensor algorithms. The initiative is being co-founded by Shimmer, Dr. Vincent van Hees, author of the GGIR software and algorithms for movement sensor calibration, sensor wear detection, and signal aggregation, and Nextbridge Health, which is developing the Nextbridge Exchange, an online marketplace and discovery platform for the clinical research community. 

An estimated 325 million people use connected wearable devices, according to IMARC. The global market for medical wearable devices is slated to reach $12.1 billion by 2021 indicates Markets&Markets. A quick check of clinicaltrials.gov that hosts a global database of clinical trials, will provide around 200 trials based on wearable devices or wearable technology. This shows that the technological advancements in connected devices have a key role to play in clinical trials.

Shimmer Research today announced that it has been honored with two GHP International Life Sciences Awards – Best Clinical Trials Wearable Sensor Technology Company USA, and Best Researcher Wearable Wireless Technology Provider 2019.

Shimmer Research and ClearSky Medical Diagnostics today announced they are partnering to bring a new level of analytic capabilities to the use of wearable sensors in clinical research. This partnership will employ Shimmer's Verisense™ wearable sensors platform, which has been designed specifically for use in clinical research, with ClearSky algorithms and machine learning to transform wearables data into actionable insights for central nervous system (CNS) diseases.

Shimmer today announced that Geoff Gill, president of Shimmer Americas, will be presenting at the Body Sensor Networks (BSN) ’19 pre-conference workshop entitled, “Using mHealth Technology to Enable the Clinical Trial of the Future.” This workshop will be held on May 19 at the University of Illinois at Chicago in Chicago, Illinios.

Shimmer announced that Paolo Bonato, PhD, director of the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital in Boston, has signed a letter of intent to employ Shimmer’s Verisense continuous monitoring platform during his next clinical trial to study motor recovery in stroke survivors.